Telbivudine: new drug. Chronic hepatitis B: similar to lamivudine.
Telbivudine does not offer any tangible advantage over existing treatments. It is better to continue to use lamivudine, which is known to prevent clinical complications and has been in use for many years.
D002986:Clinical Trials as Topic; D005060:Europe; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009705:Nucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D009705:Nucleosides; D011744:Pyrimidinones; D019259:Lamivudine